tradingkey.logo

Synergy CHC Corp

SNYR
1.830USD
+0.030+1.67%
收盘 12/19, 16:00美东报价延迟15分钟
20.59M总市值
6.50市盈率 TTM

Synergy CHC Corp

1.830
+0.030+1.67%

关于 Synergy CHC Corp 公司

Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications.

Synergy CHC Corp简介

公司代码SNYR
公司名称Synergy CHC Corp
上市日期Nov 08, 2013
CEORoss (Jack)
员工数量21
证券类型Ordinary Share
年结日Nov 08
公司地址865 Spring St
城市WESTBROOK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编04092-3828
电话16159399004
网址https://synergychc.com/
公司代码SNYR
上市日期Nov 08, 2013
CEORoss (Jack)

Synergy CHC Corp公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Jack Ross
Mr. Jack Ross
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
674.81K
+1.67%
Mr. Nitin Kaushal, CPA
Mr. Nitin Kaushal, CPA
Independent Director
Independent Director
--
--
Mr. J. Paul SoRelle
Mr. J. Paul SoRelle
Independent Director
Independent Director
--
--
Mr. Alfred Baumeler
Mr. Alfred Baumeler
President, Director
President, Director
--
--
Ms. Jaime Fickett
Ms. Jaime Fickett
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Teresa Thompson
Ms. Teresa Thompson
Director
Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Jack Ross
Mr. Jack Ross
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
674.81K
+1.67%
Mr. Nitin Kaushal, CPA
Mr. Nitin Kaushal, CPA
Independent Director
Independent Director
--
--
Mr. J. Paul SoRelle
Mr. J. Paul SoRelle
Independent Director
Independent Director
--
--
Mr. Alfred Baumeler
Mr. Alfred Baumeler
President, Director
President, Director
--
--
Ms. Jaime Fickett
Ms. Jaime Fickett
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Teresa Thompson
Ms. Teresa Thompson
Director
Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q3
FY2020
FY2019
业务USD
名称
营收
占比
Nutraceuticals
6.73M
82.79%
Consumer Goods
1.40M
17.21%
地区USD
名称
营收
占比
United States
7.95M
97.78%
Foreign countries
180.67K
2.22%
业务
地区
业务USD
名称
营收
占比
Nutraceuticals
6.73M
82.79%
Consumer Goods
1.40M
17.21%

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Gowan Private Equity, Inc.
32.70%
Knight Therapeutics (Barbados), Inc.
13.18%
Ross (Jack)
6.00%
Gratia Capital, LLC
4.93%
Heartland Advisors, Inc.
4.89%
其他
38.31%
持股股东
持股股东
占比
Gowan Private Equity, Inc.
32.70%
Knight Therapeutics (Barbados), Inc.
13.18%
Ross (Jack)
6.00%
Gratia Capital, LLC
4.93%
Heartland Advisors, Inc.
4.89%
其他
38.31%
股东类型
持股股东
占比
Corporation
49.49%
Individual Investor
6.97%
Hedge Fund
5.23%
Investment Advisor/Hedge Fund
5.13%
Investment Advisor
4.07%
Research Firm
0.14%
其他
28.97%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
15
489.86K
4.38%
-692.44K
2025Q2
20
7.35M
81.54%
-158.23K
2025Q1
20
7.51M
86.32%
+3.84M
2024Q4
17
7.37M
84.73%
+5.72M
2024Q3
6
504.50K
6.68%
-5.50M
2024Q2
6
6.00M
79.48%
+6.00M
2023Q3
6
5.96M
78.91%
--
2023Q2
6
5.96M
78.91%
--
2023Q1
6
5.96M
78.91%
--
2022Q4
6
5.96M
78.91%
--
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Gowan Private Equity, Inc.
3.68M
32.87%
--
--
Apr 21, 2025
Knight Therapeutics (Barbados), Inc.
1.48M
13.25%
--
--
Jun 11, 2025
Ross (Jack)
674.81K
6.03%
+11.10K
+1.67%
Jul 30, 2025
Gratia Capital, LLC
--
0%
-105.94K
-100.00%
Jun 30, 2025
Sanders Morris LLC
391.70K
3.5%
+18.70K
+5.01%
Sep 30, 2025
Dunhill Distribution Group, Inc.
269.63K
2.41%
--
--
Apr 21, 2025
Gowan Capital, Inc.
136.56K
1.22%
--
--
Apr 21, 2025
SoRelle (James Paul)
108.96K
0.97%
--
--
Apr 21, 2025
The Vanguard Group, Inc.
22.13K
0.2%
--
--
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Synergy CHC Corp的前五大股东是谁?

Synergy CHC Corp 的前五大股东如下:
Gowan Private Equity, Inc.持有股份:3.68M,占总股份比例:32.87%。
Knight Therapeutics (Barbados), Inc.持有股份:1.48M,占总股份比例:13.25%。
Ross (Jack)持有股份:674.81K,占总股份比例:6.03%。
Gratia Capital, LLC持有股份:0.00,占总股份比例:0.00%。
Sanders Morris LLC持有股份:391.70K,占总股份比例:3.50%。

Synergy CHC Corp的前三大股东类型是什么?

Synergy CHC Corp 的前三大股东类型分别是:
Gowan Private Equity, Inc.
Knight Therapeutics (Barbados), Inc.
Ross (Jack)

有多少机构持有Synergy CHC Corp(SNYR)的股份?

截至2025Q3,共有15家机构持有Synergy CHC Corp的股份,合计持有的股份价值约为489.86K,占公司总股份的4.38%。与2025Q2相比,机构持股有所增加,增幅为-77.17%。

哪个业务部门对Synergy CHC Corp的收入贡献最大?

在FY2025Q2,Nutraceuticals业务部门对Synergy CHC Corp的收入贡献最大,创收6.73M,占总收入的82.79%。
KeyAI